APOL1-mediated kidney disease: Overview and Implications for Care
Learn more about APOL1-Mediated Kidney Disease (AMKD)
APOL1 as a potential genetic marker for kidney disease remains a topic new to many healthcare professionals.
It is estimated that 45% of people with African ancestry in the US carry at least one high-risk APOL1 genetic variant and 13% carry two variants, which could have certain impacts on the health of a segment of your patient population.
In this webinar, nephrologist and subject matter expert, Mona Doshi, MD, presents information that will:
- Raise awareness of APOL1-mediated kidney disease among healthcare professionals
- Educate healthcare professionals about the role of these variants in kidney genetics and their potential impact in populations of African or Hispanic/Latino descent
- Highlight the need for increased genetic testing and its availability for those at risk, especially in relation to minority patients
Moderator: Silas Norman, M.D.
Speaker: Mona Doshi, MD